Randomized trialMedical2026

Adjunctive delta-9-tetrahydrocannabinol during prolonged exposure therapy for PTSD: A randomized, double-blind feasibility pilot trial with mechanistic assessment of extinction recall.

Rabinak C.; Haggarty C.; Rauch S.; Lumley M.; Kilgore P.; Iadipaolo A.; Durack S.; Thomas C.; Tucker K.; Fiskeaux M. et al. · Research square · 2026

Research summary

**Background & Methods** This double-blind, placebo-controlled pilot feasibility trial randomized 23 adults with PTSD to receive either 7.5 mg oral dronabinol (THC) or placebo prior to sessions 3-6 of massed Prolonged Exposure (PE) therapy delivered via telehealth. Primary outcomes included clinician-rated PTSD severity (CAPS-5) and self-reported symptoms (PCL-5), with mechanistic assessments of extinction recall using behavioral, psychophysiological, and neuroimaging measures. **Key Findings** • Both treatment groups demonstrated substantial reductions in clinician-rated and self-reported PTSD symptoms with improvements sustained at 3-month follow-up; 91% of participants no longer met PTSD diagnostic criteria regardless of group assignment. • Secondary improvements occurred across anxiety, depression, sleep quality, and dissociative symptoms in both conditions; descriptive analysis suggested numerically lower PTSD severity and reduced persistence of dissociative symptoms in THC-treated participants, though the study was underpowered for between-group statistical comparisons. • Neuroimaging analysis revealed that THC administration was associated with greater hippocampal differentiation between extinguished and unextinguished threat cues during extinction recall, while behavioral and psychophysiological measures showed no between-group differences, suggesting a potential neural mechanistic effect. **Dosage & Administration** 7.5 mg oral dronabinol (THC) administered prior to PE therapy sessions 3-6 (4 total doses during active treatment phase). **Safety & Adverse Effects** THC was well tolerated with no serious adverse events reported. **Evidence Quality** This pilot feasibility trial represents early-phase evidence (pre-Phase III) with significant limitations including small sample size (n=23), lack of statistical power for between-group comparisons, and underpowered mechanistic analyses. The telehealth delivery format, while pragmatic, differs from standard in-person PE protocols. Strengths include randomized double-blind design, objective neuroimaging biomarkers, and comprehensive outcome assessment across multiple symptom domains. The high response rate and maintenance of gains at follow-up are notable. However, findings are preliminary and require validation in adequately powered randomized controlled trials before clinical recommendations can be established. The study provides sufficient feasibility and safety data to justify Phase IIb/III investigation.

Summary generated by DeepWeed from the published abstract. See the original paper for full methods and results.

Journal
Research square
Year
2026
Study type
Randomized trial
Read the original paper (DOI) ↗
Ask how this study fits the wider evidence — across 26,000+ papers.
Ask DeepWeed

More recent cannabis research

This page summarises published research for informational purposes only — it isn't medical advice. Always refer to the original publication for full methods, results and limitations.

← Back to home